全文获取类型
收费全文 | 293404篇 |
免费 | 26329篇 |
国内免费 | 14049篇 |
专业分类
耳鼻咽喉 | 3270篇 |
儿科学 | 7986篇 |
妇产科学 | 4834篇 |
基础医学 | 46206篇 |
口腔科学 | 8855篇 |
临床医学 | 25113篇 |
内科学 | 41616篇 |
皮肤病学 | 6151篇 |
神经病学 | 19475篇 |
特种医学 | 6186篇 |
外国民族医学 | 149篇 |
外科学 | 26228篇 |
综合类 | 46013篇 |
现状与发展 | 64篇 |
一般理论 | 2篇 |
预防医学 | 15120篇 |
眼科学 | 6767篇 |
药学 | 23814篇 |
68篇 | |
中国医学 | 9310篇 |
肿瘤学 | 36555篇 |
出版年
2024年 | 678篇 |
2023年 | 3975篇 |
2022年 | 7636篇 |
2021年 | 10468篇 |
2020年 | 9378篇 |
2019年 | 8816篇 |
2018年 | 8978篇 |
2017年 | 9900篇 |
2016年 | 10531篇 |
2015年 | 11553篇 |
2014年 | 18008篇 |
2013年 | 20239篇 |
2012年 | 17313篇 |
2011年 | 19429篇 |
2010年 | 16306篇 |
2009年 | 15458篇 |
2008年 | 16068篇 |
2007年 | 16238篇 |
2006年 | 14692篇 |
2005年 | 13281篇 |
2004年 | 11426篇 |
2003年 | 9816篇 |
2002年 | 8042篇 |
2001年 | 6990篇 |
2000年 | 5852篇 |
1999年 | 5145篇 |
1998年 | 4653篇 |
1997年 | 4199篇 |
1996年 | 3779篇 |
1995年 | 3365篇 |
1994年 | 2923篇 |
1993年 | 2421篇 |
1992年 | 2058篇 |
1991年 | 1829篇 |
1990年 | 1548篇 |
1989年 | 1336篇 |
1988年 | 1176篇 |
1987年 | 975篇 |
1986年 | 880篇 |
1985年 | 1191篇 |
1984年 | 1028篇 |
1983年 | 713篇 |
1982年 | 830篇 |
1981年 | 627篇 |
1980年 | 552篇 |
1979年 | 393篇 |
1978年 | 294篇 |
1977年 | 235篇 |
1976年 | 195篇 |
1975年 | 92篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
73.
《Journal of Clinical Orthopaedics and Trauma》2020,11(2):184-190
ObjectiveProvide an update of the management options for early onset scoliosis patients, including general assessment, conservative and surgical options.MethodsWe included the updated information about the assessment and management options of Early Onset Scoliosis, taking into consideration the non-fusion methods, including the burden on the patient and their family.ResultsWith the heterogeneity of this population, it is difficult to get a consensus about a unified protocol for management. Accordingly, the surgeon dealing with these cases needs to be aware of the broad range of surgical and non-surgical methods when treating these patients.ConclusionThe main aim of early onset scoliosis treatment is to gain a flexible spine associated with normal lung development and thoracic growth. Management needs to be individualized between the surgeon and patient in relation to the etiology and patient conditions. 相似文献
74.
75.
《Vaccine》2020,38(10):2315-2325
In the preparation of glycoconjugate vaccines in clinical practice, two highly immunogenic carrier proteins, CRM197 and tetanus toxoid (TT), are predominantly conjugated with the capsular polysaccharides (CPSs) of bacterial pathogens. In addition, TT has long been used as an effective vaccine to prevent tetanus. While these carrier proteins play an important role in immunogenicity and vaccine design alike, their defined human major histocompatibility complex class II (MHCII) T cell epitopes are inadequately characterized. In this current work, we use mass spectrometry to identify the peptides from these carrier proteins that are naturally processed and presented by human B cells via MHCII pathway. The MHCII-presented peptides are screened for their T cell stimulation using primary CD4+ T cells from four healthy adult donors. These combined methods reveal a subset of eleven CD4+ T cell epitopes that proliferate and stimulate human T cells with diverse MHCII allelic repertoire. Six of these peptides stand out as potential immunodominant epitopes by responding in three or more donors. Additionally, we provide evidence of these natural epitopes eliciting more significant T cell responses in donors than previously published TT peptides selected from T cell epitope screening. This study serves toward understanding carrier protein immune responses and thus enables the use of these peptides in developing novel knowledge-based vaccines to combat persisting problems in glycoconjugate vaccine design. 相似文献
76.
77.
Sickle cell disease (SCD) is a highly complex inherited disorder of hemoglobin structure. Although the molecular lesion is a single-point mutation, the sickle gene is pleiotropic in nature causing multiple phenotypic expressions that constitute the various complications of the disease. Its manifestations could be acute, chronic, nociceptive, neuropathic that could occur singly or in various combinations. Pain continues to be the major factor of SCD phenotypic complications and the most common cause of admissions to the Emergency Department and/or the hospital. Although progress has been made in understanding the pathophysiology of SCD as well as in developing curative therapies such as hematopoietic stem cell transplantation and gene therapy, effective pain management continues to lag behind. Palliative therapies continue to be the major approach to the management of SCD and its complications. The advent of hydroxyurea made partial success in preventing the frequency of vaso-occlusive crises and l-glutamine awaits post-trial confirmation of benefits. The search for additional pharmacotherapeutic agents that could be used singly or in combination with hydroxyurea and/or l-glutamine awaits their dawn hopefully in the near future. The purpose of this review is to describe the various manifestations of SCD, their pathophysiology and their current management. Recent impressive advances in understanding the pathophysiology of pain promise the determination of agents that could replace or minimize the use of opioids. 相似文献
78.
79.
80.